SEC-sourced researchBeta

FDMT

4D Molecular Therapeutics, Inc.

US markets

Data passport

CIK: 0001650648
Exchange: Nasdaq
Business activity: — · SIC 2836
Financial inputs: 6/6
Filing date: Oct 7, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 8:04 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

FDMT · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2024	37,000.0000	Mar 18, 2026
December 2025	85,209,000.0000	Mar 18, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	85,209,000.0000	-140,109,000.0000	-109,082,000.0000	566,711,000.0000	61,047,000.0000	Mar 18, 2026
December 2024	37,000.0000	-160,868,000.0000	-134,585,000.0000	560,384,000.0000	49,778,000.0000	Mar 18, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$85.21M	December 2025	Mar 18, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$37K	December 2024	Mar 18, 2026	10-K
Net incomeNetIncomeLoss	-$140.11M	December 2025	Mar 18, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	-$109.08M	December 2025	Mar 18, 2026	10-K
Total assetsAssets	$566.71M	December 2025	Mar 18, 2026	10-K
Total liabilitiesLiabilities	$61.05M	December 2025	Mar 18, 2026	10-K

New filings

Explore methodology ↗